Centessa Pharmaceuticals
Merger of 10 privately held biotech companies with highly validated programs, including Cappella Biosciences, to operate under Centessa umbrella
Centessa Pharmaceuticals was launched in February 2021 as a novel asset-centric pharmaceutical company designed and built to advance a portfolio of highly validated programs.
The company was created by the merger of ten privately held biotech companies with highly validated programs including Advent Life Sciences’ founded Capella Biosciences.
Capella Bioscience has two programs: CBS001, a neutralizing therapeutic monoclonal antibody to the inflammatory membrane form of LIGHT (known as TNFSF14), for the treatment of idiopathic pulmonary fibrosis, and CBS004, a therapeutic monoclonal antibody to blood dendritic cell antigen 2 (BDCA2), for the treatment of lupus erythematosus (systemic and cutaneous) and systemic sclerosis.
CEO Steve Holmes
Advent Contact Raj Parekh
Publicly Listed
Advent Life Sciences Announces Growth of Investment Team with Three Senior Appointments
Press Release. 26 May 2022, London, UK: Advent Life Sciences, a leading transatlantic venture and growth investor focused on building innovative life science companies in the UK, Europe, and…
Read More
Advent Life Sciences’ founded Amphista Therapeutics raises $53M in oversubscribed Series B round to advance next generation targeted protein degradation assets
Press Release. This investment will fund Amphista Therapeutics’ growing pipeline of potent and selective bifunctional molecules, known as ‘Amphistas’ to the clinic and extend its proprietary platform. London, UK,…
Read More
